Antje Krohn

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.

Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer.

Journal: Oncotarget

Published: August 27, 2015

Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer.

Journal: International journal of oncology

Published: November 25, 2014

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: January 08, 2014

TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.

TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.

Journal: European urology

Published: November 12, 2013

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer.

Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer.

Journal: International journal of cancer

Published: October 17, 2013

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

Journal: Cancer research

Published: March 16, 2013

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: September 04, 2012

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.

Journal: The Journal of pathology

Published: August 07, 2012

Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer.

Altered PTEN function caused by deletion or gene disruption is associated with poor prognosis in rectal but not in colon cancer.

Journal: Human pathology

Published: June 07, 2012

PTEN deletion is rare but often homogeneous in gastric cancer.

PTEN deletion is rare but often homogeneous in gastric cancer.

Journal: Journal of clinical pathology

Published: May 29, 2012

P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region.

P53 immunohistochemical expression does not correlate with clinical features in 207 carcinomas of the oral cavity and in the head and neck region.

Journal: Clinical oral investigations

Published: May 22, 2012

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.

Journal: Cancer cell

Published: May 10, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026